Non-invasive predictive score of fibrosis stages in chronic hepatitis C patients based on epithelial membrane antigen in the blood in combination with routine laboratory markers

Hepatology Research

Volumn 41, Issue 11, 2011, Pages 1075-1084

  Attallah, Abdelfattah M ^a   Abdallah, Sanaa O ^b   El Sayed, Amr S ^b   Omran, Mohamed M ^a   El Bendary, Mahmoud ^c   Farid, Khaled ^c   Kadry, Mohamed ^a  

^a Biotechnology Research Center of New Damietta   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

^c MANSOURA UNIVERSITY   (Egypt)

Author keywords

Blood marker; Epithelial membrane antigen; Hepatitis C virus; Liver fibrosis

Indexed keywords

ASPARTATE AMINOTRANSFERASE; EPITHELIAL MEMBRANE ANTIGEN;

ADULT; AGED; ANTIGEN PURIFICATION; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISCRIMINANT ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS C; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NON INVASIVE PROCEDURE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; VALIDATION STUDY; WESTERN BLOTTING;

EID: 84861108591     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2011.00862.x     Document Type: Article

References (36)

1. Han KH, Yoon KT. New diagnostic method for liver fibrosis and cirrhosis. Intervirol 2008; 51: 1-16.
2. Westin J, Lagging LM, Wejstål R et al. Interobserver study of liver histology using the Ishak score in patients with chronic hepatitis C virus infection. Liver 1999; 19: 183-7.
3. Regev A, Berho M, Jeffers LJ et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002; 97: 2614-18.
4. Guha IN, Rosenberg WM. Noninvasive assessment of liver fibrosis: serum markers, imaging and other modalities. Liver Dis 2008; 12: 883-900.
5. Leroy V. Other non-invasive markers of liver fibrosis. Gastroenterol Clin Biol 2008; 32: 52-7.
6. Adams LA. Biomarkers of liver fibrosis. Gastroenterol Hepatol 2011; 26: 802-9.
7. Jarcuska P, Janicko M, Veselíny E, Jarcuska P, Skladanỳ L. Circulating markers of liver fibrosis progression. Clin Chim Acta 2010; 411: 1009-17.
8. Lackner C, Struber G, Liegl B et al. Comparison and validation of simple noninvasive tests for prediction of fibrosis in chronic hepatitis C. Hepatol 2005; 41: 1376-82.
9. Fabris C, Smirne C, Toniutto P et al. Assessment of liver fibrosis progression in patients with chronic hepatitis C and normal alanine aminotransferase values: the role of AST to the platelet ratio index. Clin Biochem 2006; 39: 339-43.
10. Heyderman E, Steele K, Ormerod MG. A new antigen on the epithelial membrane: its immunoperoxidase localization in normal and neoplastic tissue. J Clin Pathol 1979; 32: 35-9.
11. Langner C, Ratschek M, Rehak P et al. Expression of MUC1(EMA) and E-cadherin in renal cell carcinoma: a systematic immunohistochemical analysis of 188 cases. Mod Pathol 2004; 7: 180-88.
12. Leong CF, Raudhawati O, Cheong SK et al. Epithelial membrane antigen (EMA) or (MUC1) expression in monocytes and monoblasts. Pathol 2003; 35: 422-27.
13. ten Berge RL, Snijdewint FG, von Mensdorff-Pouilly S et al. MUC1 (EMA) is preferentially expressed by ALK positive anaplastic large cell lymphoma, in the normally glycosylated or only partly hypoglycosylated form. J Clin Pathol 2001; 54: 933-39.
14. Sloane JP, Ormerod MG. Distribution of epithelial membrane antigen in normal and neoplastic tissues and its value in diagnostic tumor pathology. Cancer 1981; 47: 1786-95.
15. Attallah AM, Ismail H, Shiha GE et al. Immunochemical identification and partial characterization of a native hepatitis C viral non-structural 4 antigen in sera of HCV infected patients. Clin Chim Acta 2008; 388: 115-22.
16. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349: 825-32.
17. Wai CT, Greenson JK, Fontana RJ et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatol 2003; 38: 518-26.
18. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-5.
19. Towbin H, Stachlin T, Gordou J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets procedure and some applications. Proc Natl Acad Sci USA 1979; 76: 4350-4.
20. Lowry OH, Rosenbrough NJ, Farr AL et al. Protein measurement with folin - phenol reagent. J Biol Chem 1951; 193: 265-75.
21. Ormerod MG, Steele K, Westwood JH et al. Epithelial membrane antigen: partial purification, assay and properties. Br J Cancer 1983; 48: 533-41.
22. Hendrick JC, Gilis F, Franchimont P. Assay of epithelial membrane antigen (EMA) in human serum by ELISA. Eur J Cancer Clin Oncol 1986; 22: 1223-9.
23. von Mensdorff-Pouilly S, Snijdewint FG, Verstraeten AA, Verheijen RH, Kenemans P. Human MUC1 mucin: a multifaceted glycoprotein. Int J Biol Markers 2000; 15: 343-56.
24. Yuan SF, Li KZ, Wang L et al. Expression of MUC1 and its significance in hepatocellular and cholangiocarcinoma tissue. W J Gastroenterol 2005; 14 (11): 4661-6.
25. Said M. Evaluation of routine biochemical indices and a-fetoprotein versus histology in chronic hepatitis C patients. Arab J Gastroenterol 2009; 10: 87-91.
26. Shin WG, Park SH, Jang MK et al. Aspartate aminotransferase to platelet ratio index (APRI) can predict liver fibrosis in chronic hepatitis B. Dig Liver Dis 2008; 40: 267-74.
27. Fahim FA, Esmat AY, Hassan GK, Abdel-Bary A. Biochemical changes in patients with combined chronic schistosomiasis and viral hepatitis C infections. Dis Markers 2000; 16: 111-8.
28. Attallah AM, Mosa TE, Omran MM et al. Immunodetection of collagen types I, II, III, and IV for differentiation of liver fibrosis stages in patients with chronic HCV. J Immunoassay Immunochem 2007; 28: 155-68.
29. Attallah AM, Shiha GE, Omran MM, Zalata KR. Discriminant score based on four routine laboratory blood tests for accurate diagnosis of severe fibrosis and/or liver cirrhosis in Egyptian patients with chronic hepatitis C. Hepatol Res 2006; 34: 163-9.
30. Attallah AM, Toson EA, El-Waseef AM et al. Discriminant function based on hyaluronic acid and its degrading enzymes and degradation products for differentiating cirrhotic from non-cirrhotic liver diseased patients in chronic HCV infection. Clin Chim Acta 2006; 369: 66-72.
31. Halfon P, Bourlière M, Pénaranda G et al. Serum markers of non-invasive fibrosis in chronic hepatitis C virus infection. Rev Med Interne 2006; 27: 751-61.
32. Adams LA, Bulsara M, Rossi E et al. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem 2005; 51: 1867-73.
33. Leroy V, Monier F, Bottari S et al. Circulating matrix metalloproteinases 1, 2, 9 and their inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C: comparison with PIIINP and hyaluronic acid. Am J Gastroenterol 2004; 99: 271-9.
34. Sud A, Hui JM, Farrell GC et al. Improved prediction of fibrosis in chronic hepatitis C using measures of insulin resistance in a probability index. Hepatol 2004; 39: 1239-47.
35. Forns X, Ampurdanes S, Llovet JM et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatol 2002; 36: 986-92.
36. Berenguer J, Bellón JM, Miralles P et al. Identification of liver fibrosis in HIV/HCV-coinfected patients using a simple predictive model based on routine laboratory data. J Viral Hepat 2007; 14: 859-69.